Chris Shibutani
Stock Analyst at Goldman Sachs
(3.98)
# 540
Out of 4,905 analysts
96
Total ratings
53.85%
Success rate
11.48%
Average return
Main Sectors:
Stocks Rated by Chris Shibutani
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PCVX Vaxcyte | Maintains: Buy | $138 → $100 | $37.37 | +167.59% | 2 | Apr 1, 2025 | |
| ERAS Erasca | Maintains: Buy | $3.5 → $3 | $1.49 | +101.34% | 7 | Mar 21, 2025 | |
| MCRB Seres Therapeutics | Maintains: Sell | $20 → $15 | $14.08 | +6.53% | 4 | Mar 14, 2025 | |
| ALKS Alkermes | Maintains: Buy | $30 → $32 | $29.36 | +8.99% | 7 | Feb 14, 2025 | |
| BNTX BioNTech SE | Upgrades: Buy | $90 → $137 | $111.04 | +23.38% | 7 | Nov 8, 2024 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $30 → $33 | $9.67 | +241.26% | 3 | Nov 7, 2024 | |
| UTHR United Therapeutics | Maintains: Neutral | $243 → $302 | $297.33 | +1.57% | 4 | Nov 1, 2024 | |
| RPRX Royalty Pharma | Maintains: Buy | $50 → $51 | $35.47 | +43.78% | 3 | Aug 14, 2024 | |
| JNJ Johnson & Johnson | Maintains: Neutral | $160 → $155 | $162.98 | -4.90% | 3 | Jul 19, 2024 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Neutral | $3 → $4 | $8.28 | -51.69% | 8 | Jul 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $20 | $9.64 | +107.47% | 5 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $650 → $723 | $761.50 | -5.06% | 6 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $29 → $26 | $21.65 | +20.09% | 1 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $134 → $153 | $134.11 | +14.09% | 2 | Jan 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $173 | $191.40 | -9.61% | 4 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $26.67 | - | 4 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $81 → $69 | $48.06 | +43.57% | 5 | Oct 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $13 | $19.88 | -34.61% | 2 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $20 → $23 | $39.05 | -41.10% | 3 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $3.27 | +1,429.05% | 1 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $52 | $46.40 | +12.08% | 2 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $47 → $60 | $24.58 | +144.10% | 2 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $18 | $6.38 | +182.13% | 4 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $6.86 | +147.81% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.52 | - | 1 | Jul 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $4.52 | - | 1 | Feb 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $3.36 | - | 4 | Jan 24, 2018 |
Vaxcyte
Apr 1, 2025
Maintains: Buy
Price Target: $138 → $100
Current: $37.37
Upside: +167.59%
Erasca
Mar 21, 2025
Maintains: Buy
Price Target: $3.5 → $3
Current: $1.49
Upside: +101.34%
Seres Therapeutics
Mar 14, 2025
Maintains: Sell
Price Target: $20 → $15
Current: $14.08
Upside: +6.53%
Alkermes
Feb 14, 2025
Maintains: Buy
Price Target: $30 → $32
Current: $29.36
Upside: +8.99%
BioNTech SE
Nov 8, 2024
Upgrades: Buy
Price Target: $90 → $137
Current: $111.04
Upside: +23.38%
Syndax Pharmaceuticals
Nov 7, 2024
Maintains: Buy
Price Target: $30 → $33
Current: $9.67
Upside: +241.26%
United Therapeutics
Nov 1, 2024
Maintains: Neutral
Price Target: $243 → $302
Current: $297.33
Upside: +1.57%
Royalty Pharma
Aug 14, 2024
Maintains: Buy
Price Target: $50 → $51
Current: $35.47
Upside: +43.78%
Johnson & Johnson
Jul 19, 2024
Maintains: Neutral
Price Target: $160 → $155
Current: $162.98
Upside: -4.90%
Amylyx Pharmaceuticals
Jul 12, 2024
Maintains: Neutral
Price Target: $3 → $4
Current: $8.28
Upside: -51.69%
May 6, 2024
Maintains: Neutral
Price Target: $18 → $20
Current: $9.64
Upside: +107.47%
Apr 11, 2024
Maintains: Neutral
Price Target: $650 → $723
Current: $761.50
Upside: -5.06%
Mar 1, 2024
Maintains: Neutral
Price Target: $29 → $26
Current: $21.65
Upside: +20.09%
Jan 25, 2024
Maintains: Buy
Price Target: $134 → $153
Current: $134.11
Upside: +14.09%
Dec 11, 2023
Upgrades: Buy
Price Target: $173
Current: $191.40
Upside: -9.61%
Nov 9, 2023
Upgrades: Outperform
Price Target: n/a
Current: $26.67
Upside: -
Oct 30, 2023
Maintains: Buy
Price Target: $81 → $69
Current: $48.06
Upside: +43.57%
Mar 3, 2023
Maintains: Neutral
Price Target: $15 → $13
Current: $19.88
Upside: -34.61%
Mar 1, 2023
Maintains: Neutral
Price Target: $20 → $23
Current: $39.05
Upside: -41.10%
Dec 19, 2022
Initiates: Buy
Price Target: $50
Current: $3.27
Upside: +1,429.05%
Dec 16, 2022
Maintains: Buy
Price Target: $40 → $52
Current: $46.40
Upside: +12.08%
Dec 13, 2022
Upgrades: Buy
Price Target: $47 → $60
Current: $24.58
Upside: +144.10%
Nov 8, 2022
Maintains: Neutral
Price Target: $13 → $18
Current: $6.38
Upside: +182.13%
Sep 7, 2021
Initiates: Buy
Price Target: $17
Current: $6.86
Upside: +147.81%
Jul 14, 2020
Initiates: Outperform
Price Target: n/a
Current: $1.52
Upside: -
Feb 10, 2020
Initiates: Outperform
Price Target: n/a
Current: $4.52
Upside: -
Jan 24, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $3.36
Upside: -